257 related articles for article (PubMed ID: 27153536)
21. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
23. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
[TBL] [Abstract][Full Text] [Related]
24. Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization.
Ramirez UD; Nikonova AS; Liu H; Pecherskaya A; Lawrence SH; Serebriiskii IG; Zhou Y; Robinson MK; Einarson MB; Golemis EA; Jaffe EK
BMC Cancer; 2015 May; 15():436. PubMed ID: 26016476
[TBL] [Abstract][Full Text] [Related]
25. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42.
Hirsch DS; Shen Y; Wu WJ
Cancer Res; 2006 Apr; 66(7):3523-30. PubMed ID: 16585176
[TBL] [Abstract][Full Text] [Related]
26. Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells.
Hyatt DC; Ceresa BP
Exp Cell Res; 2008 Nov; 314(18):3415-25. PubMed ID: 18817771
[TBL] [Abstract][Full Text] [Related]
27. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
Chan KC; Knox WF; Gee JM; Morris J; Nicholson RI; Potten CS; Bundred NJ
Cancer Res; 2002 Jan; 62(1):122-8. PubMed ID: 11782368
[TBL] [Abstract][Full Text] [Related]
28. PTPα-mediated Src activation by EGF in human breast cancer cells.
Wang J; Yu L; Zheng X
Acta Biochim Biophys Sin (Shanghai); 2013 Apr; 45(4):320-9. PubMed ID: 23532252
[TBL] [Abstract][Full Text] [Related]
29. α-Lipoic acid inhibits human lung cancer cell proliferation through Grb2-mediated EGFR downregulation.
Yang L; Wen Y; Lv G; Lin Y; Tang J; Lu J; Zhang M; Liu W; Sun X
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):325-331. PubMed ID: 28993193
[TBL] [Abstract][Full Text] [Related]
30. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells.
Kuribayashi A; Kataoka K; Kurabayashi T; Miura M
Endocrinology; 2004 Nov; 145(11):4976-84. PubMed ID: 15271882
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
33. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
34. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
Zhang J; Wang J; Guo Q; Wang Y; Zhou Y; Peng H; Cheng M; Zhao D; Li F
Cancer Lett; 2012 Apr; 317(1):24-32. PubMed ID: 22085492
[TBL] [Abstract][Full Text] [Related]
35. Palmitoylation of the EGFR ligand Spitz by Rasp increases Spitz activity by restricting its diffusion.
Miura GI; Buglino J; Alvarado D; Lemmon MA; Resh MD; Treisman JE
Dev Cell; 2006 Feb; 10(2):167-76. PubMed ID: 16459296
[TBL] [Abstract][Full Text] [Related]
36. Palmitoylation of proteins in cancer.
Resh MD
Biochem Soc Trans; 2017 Apr; 45(2):409-416. PubMed ID: 28408481
[TBL] [Abstract][Full Text] [Related]
37. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.
Dong Y; Li A; Wang J; Weber JD; Michel LS
Cancer Res; 2010 Jul; 70(13):5465-74. PubMed ID: 20570903
[TBL] [Abstract][Full Text] [Related]
38. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells.
Kruger JS; Reddy KB
Mol Cancer Res; 2003 Sep; 1(11):801-9. PubMed ID: 14517342
[TBL] [Abstract][Full Text] [Related]
39. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Sordella R; Bell DW; Haber DA; Settleman J
Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
